Summary of selected cases.

Subjects were divided in three groups according to neuropathological and clinical criteria: clinic-pathological Alzheimer’s disease (CP-AD), pathological/preclinical Alzheimer’s disease (P-AD), and normal older individuals (N). Sample ID, sample identification; Age, age at death in years; F, female; M, male; Braak, Braak stage; CERAD, Consortium to Establish a Registry for Alzheimeŕs Disease score; CDR, Clinical Dementia Ratio score; PMI, post-mortem interval in hours.

本研究对象依据神经病理学与临床标准划分为三组：临床病理型阿尔茨海默病（clinic-pathological Alzheimer’s disease, CP-AD）、病理/临床前阿尔茨海默病（pathological/preclinical Alzheimer’s disease, P-AD）以及正常老年个体（N）。各字段含义如下：Sample ID为样本编号；Age指死亡时年龄（单位：年）；F代表女性（female），M代表男性（male）；Braak为Braak分期（Braak stage）；CERAD为阿尔茨海默病登记联盟（Consortium to Establish a Registry for Alzheimer’s Disease, CERAD）评分；CDR为临床痴呆评定比值（Clinical Dementia Ratio, CDR）评分；PMI为死后间隔时间（post-mortem interval, PMI），单位为小时。